Selina M. Luger

Hospital of the University of Pennsylvania — United States

Medicine · Health Sciences

64h-index21.4kcitations642works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(298), Acute Lymphoblastic Leukemia research(214), Hematopoietic Stem Cell Transplantation(100), Chronic Myeloid Leukemia Treatments(100), Chronic Lymphocytic Leukemia Research(62)

Publications641 total

Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia
JACC CardioOncology·2026Open Access
Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia
Blood·2025Open Access
IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia
Blood·2025Open Access
Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles
Blood·2025Open Access
Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.
Blood·2025
Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study
Blood·2025
UBA1a dependency leads to synthetic lethality in vacuoles, E1-ligase, x-linked, auto-inflammatory, somatic (VEXAS) syndrome
Blood·2025
Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab
Blood·2025
Phase II Results of ECOG-ACRIN EA9152: A multicenter study of liposomal vincristine (L-VCR) or vincristine sulfate (VCR) and venetoclax (VEN) in relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL)
Blood·2025Open Access
Longitudinal genomic and cytogenetic dynamics in myelodysplastic syndromes (MDS): Insights into clonal evolution and disease progression
Blood·2025Open Access
Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.
Blood·2025
Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials
Blood·2025
Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial
Blood·2025Open Access
Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study
Blood·2025Open Access
Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL
Blood Advances·2025Open Access
QUANTUM-WILD: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB IN COMBINATION WITH CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN FLT3-ITD–NEGATIVE ACUTE MYELOID LEUKEMIA
Hematology Transfusion and Cell Therapy·2025Open Access
A CHIP off the old (MDS) block
Haematologica·2025· 1 citedOpen Access
AML-995: QuANTUM-Wild: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in FLT3-ITD–Negative Acute Myeloid Leukemia (AML)
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: AML-995 QuANTUM-Wild: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in FLT3-ITD–Negative Acute Myeloid Leukemia (AML)
Clinical Lymphoma Myeloma & Leukemia·2025
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features
Nature Cancer·2025· 12 citedOpen Access
page 1 of 33Next →

Frequent Co-authors

Elisabeth Paietta(24), Martin S. Tallman(24), Mark R. Litzow(23), Jacob M. Rowe(21), Hillard M. Lazarus(19), Charles G. Mullighan(11), Janis Racevskis(9), Kathryn G. Roberts(9), Wendy Stock(9), Cheryl L. Willman(9), Rhett P. Ketterling(8), Adele K. Fielding(8), David I. Marks(8), Edward A. Stadtmauer(8), Georgina Buck(7), Anthony H. Goldstone(7), Peter H. Wiernik(7), Richard C. Harvey(7), Hugo F. Fernández(6), Zhuoxin Sun(6)